AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02937844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m\^2, d1-3
Study NCT06303830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium nitrate
Description: Sodium Nitrate
Study NCT06303830 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium nitrate
Description: Sodium Nitrate
Study NCT02788136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
Study NCT02788136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
Study NCT03372486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus naloxone
Description: Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
Study NCT03372486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
Study NCT00278564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: Autologous hematopoietic stem cell transplantation
Study NCT00278564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00278564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Study NCT00278564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG(rabbit)
Study NCT00278564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study NCT00278564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT00278564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Study NCT06358742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZCT toothpaste
Study NCT06358742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste
Study NCT02628522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADRCs therapy
Description: Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
Study NCT02628522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution
Description: Adipose derived regenerative cell isolation
Study NCT02628522 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tulip cannulas
Description: Lipoaspiration
Study NCT02628522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20mL Lidocaine 2% and Epinephrine 1:100 000
Description: Infiltration prior to liposuction
Study NCT03706833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards PASCAL System
Description: Transcatheter mitral valve repair with the Edwards PASCAL System
Study NCT03706833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Mitraclip System
Description: Transcatheter mitral valve repair with the Abbott Mitraclip System
Study NCT03382873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Lifestyle Balance (GLB)
Description: The intervention included the following key features: group-based sessions led by a lifestyle coach; a structured, state-of-the-art, 16-session core-curriculum that emphasized behavioral self-management strategies for weight loss and physical activity; 8-months of extended care with bimonthly or monthly sessions; self-monitoring of diet and physical activity.
Study NCT03382873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Plus (GLB+)
Description: The GLB+ intervention arm included participants who did not achieve the targeted percent weight loss by week 5 and incorporated enhanced training in values clarification, mindful decision making, planning, and problem solving. GLB+ included the same number of group-based sessions as GLB.
Study NCT00576602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
Study NCT00576602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive treatment
Description: As prescribed
Study NCT04289285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306 450mg SC Q4W
Description: Subjects will receive IBI306 450mg every 4 weeks subcutaneously.
Study NCT04289285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC Q4W
Description: Subjects will receive placebo every 4 weeks subcutaneously.
Study NCT04289285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI306 600mg SC Q6W
Description: Subjects will receive IBI306 600mg every 6 weeks subcutaneously.
Study NCT04289285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC Q6W
Description: Subjects will receive placebo every 6 weeks subcutaneously.
Study NCT03114046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower extremity Constraint-induced movement therapy(LE-CIMT)
Description: Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.~Both caregivers and participants will be individually interviewed before and after treatment.
Study NCT06120062 — intervention group
Intervention type: OTHER
Intervention: swaddled
Description: the 1st experimental group were swaddled
Study NCT06120062 — intervention group
Intervention type: OTHER
Intervention: mother's breast milk odor
Description: the 2nd experimental group were made to inhale mother's breast milk odor
Study NCT06120062 — intervention group
Intervention type: OTHER
Intervention: both swaddled and made to inhale mother's breast milk odor
Description: the 3rd experimental group were both swaddled and made to inhale mother's breast milk odor
Study NCT06120062 — intervention group
Intervention type: OTHER
Intervention: No procedure
Description: No procedure was applied to the infants in the control group.
Study NCT02143674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle stretching and Strength Training
Description: Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.~Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol.
Study NCT02143674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educated about physical exercises
Study NCT03172793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin Injection
Description: Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
Study NCT02440997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Study NCT04643730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure methods
Description: Acupressure on the KI3 and St36 points applied to the babies in the acupressure group for a total of 7 minutes before the heel prick
Study NCT04643730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Reflexology Methods
Description: Foot reflexology was applied to the babies in the foot reflexology group for a total of 7 minutes before the heel prick
Study NCT02440997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot bath
Study NCT02440997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: foot bath
Study NCT01228539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARGET (Trauma Affect Regulation)
Description: TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
Study NCT01228539 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Cognitive behavior therapy with trauma memory exposure
Study NCT02759380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phytoestrogen-rich foods
Description: The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
Study NCT00890864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation for breast screening
Description: Invitation for breast screening to women in different age groups
Study NCT03478007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Technology
Description: Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
Study NCT03478007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention Technology Plus Coaching
Description: Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
Study NCT04643730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Grup
Description: No pre-application was made to the babies in the control group as a routine procedure.
Study NCT03012217 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Study NCT02106221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
Study NCT02106221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Will receive payments based on achievement in meeting goals.
Study NCT04340674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation based on aerobic exercise
Description: To perform different whole body aerobic exercises moderately intense according to Borg scale.
Study NCT01591395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic total extraperitoneal hernia repair (single port vs. multiport)
Description: comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
Study NCT01041508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry (30, 40 or 52 mg/m2).
Study NCT01041508 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines.
Study NCT01041508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
Study NCT01041508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine is given IV based on body weight at:~* Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs).~* Age > 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)~Cyclosporine should be started on day -1 after completion of Clofarabine. Levels should be maintained between 300-400 ng/ml.
Study NCT01041508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: MMF will be at 15 mg/kg, based on adjusted body weight, q 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant. Oral doses will be rounded to the nearest 250 mg (capsules are 250 mg). MMF is also available in oral suspension form. MMF will be given until day +40 post transplant and then tapered by 10% per week to be discontinued by day +90.
Study NCT02424331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lips Breathing
Description: Pursed Lips Breathing for six minutes.
Study NCT02424331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quiet Breathing
Study NCT04494373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20090
Description: A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
Study NCT04494373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xgeva®
Description: A human IgG2 monoclonal antibody with affinity and specificity for human RANKL
Study NCT01015183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
Study NCT01015183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: as the same of intervention group
Study NCT05010382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement surgery
Description: Under local anaesthesia, full-thickness mucoperiosteal flaps were elevated, the alveolar ridge measured, and a proper implant dimension (3.75 mm and 4.25 mm diameter; 8 mm, 10 mm and 11.5 mm length) and position selected. After site preparation, each patient was randomly allocated to the test or the control group. Patients in the test group received a modified implant design with the coronal third presenting a machined surface (hybrid surface (HS) group), while in the control group the same implant design with a titanium rough surface up to the implant shoulder was used (rough surface (RS) group). Implants were placed 1 mm sub-crestally. In the case of dehiscence or fenestrations around the implant, the patient was excluded from the study. Once inserted, healing abutments (ranging between 3 -5 mm) were placed, and flaps sutured around the abutments to allow for a transmucosal healing.
Study NCT03791528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio-taping treatment group
Description: In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the SIJ, and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire.
Study NCT00611650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given orally
Study NCT00611650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02810223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: 2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
Study NCT02250027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules at once, 3 times a day, for 7 days
Study NCT02250027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 capsules at once, 3 times a day, for 7 days
Study NCT00503828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derris scandens Benth extracts
Description: Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
Study NCT00503828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: Naproxen 500 mg/day for 4 weeks
Study NCT00765024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: single dose of 200 mcg/kg
Study NCT03228043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
Study NCT00765024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: two single dose of 200mcg/kg in 2 weeks
Study NCT00765024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole 7 days
Study NCT00769574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological analysis of biomarkers
Description: Biological analysis of biomarkers
Study NCT00769574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biological analysis of biomarkers
Description: Biological analysis of biomarkers
Study NCT03317132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPS
Description: One year of IPS Support
Study NCT02085915 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: strip Peri Screen
Study NCT01351246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Based Self-help Workbook + Counseling Telephone
Description: Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, \& Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, \& Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
Study NCT01805271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: (5 or 10 mg/day, i.e. 1 or 2 tablets/day)
Study NCT01805271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (5 or 10 mg/day, i.e. 1 or 2 tablets/day)
Study NCT04411524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Before neo-CRT: 2 cycles of PD-1 antibody After neo-CRT: 3 cycles of PD-1 antibody
Study NCT04411524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: During neo-CRT: 625mg/m2 bid Monday-Friday per week
Study NCT04411524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
Study NCT04411524 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy
Description: IMRT DT: 50Gy/25Fx
Study NCT00137865 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EGEN-001 (phIL-12-005/PPC)
Study NCT02812355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study NCT02812355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT02449720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Intraperitoneal instillation and infusion
Study NCT02449720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Saline
Description: Intraperitoneal instillation and infusion
Study NCT01600508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videoconference stoma care
Description: Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
Study NCT01600508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videoconference stoma care
Description: Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
Study NCT02015702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-on-one physician training
Description: Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
Study NCT02015702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual training
Description: Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
Study NCT02015702 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual training
Description: Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.